var data={"title":"Diphtheria, tetanus toxoids, and acellular pertussis vaccine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Diphtheria, tetanus toxoids, and acellular pertussis vaccine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6048?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-drug-information\" class=\"drug drug_general\">see &quot;Diphtheria, tetanus toxoids, and acellular pertussis vaccine: Drug information&quot;</a> and <a href=\"topic.htm?path=diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Diphtheria, tetanus toxoids, and acellular pertussis vaccine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161261\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Adacel;</li>\n      <li>Boostrix;</li>\n      <li>Daptacel;</li>\n      <li>Infanrix</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161262\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Adacel;</li>\n      <li>Boostrix</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058014\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Vaccine</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Vaccine, Inactivated Bacteria</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058008\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-drug-information\" class=\"drug drug_general\">see &quot;Diphtheria, tetanus toxoids, and acellular pertussis vaccine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Consult CDC/ACIP annual immunization schedules for additional information including specific detailed recommendations for catch-up scenarios and/or care of patients with high-risk conditions. According to ACIP, doses administered &le;4 days before minimum interval or age are considered valid; however, local or state mandates may supersede this timeframe (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Primary immunization:</b> Infants and Children 6 weeks to &lt;7 years: <b>Note:</b> Whenever possible, the same product should be used for all doses. Preterm infants should be vaccinated according to their chronological age from birth. DTaP (Daptacel, Infanrix): IM: 0.5 mL per dose for a total of 5 doses administered as follows (ACIP [Robinson 2017]):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Three doses, usually given at 2-, 4-, and 6 months of age; may be given as early as 6 weeks of age and repeated every 4 to 8 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fourth dose: Given at ~15 to 20 months of age but at least 6 months after third dose. The fourth dose may be given as early as 12 months of age.<b> Note</b><b>: </b>If the 4<sup>th</sup> dose is inadvertently administered early (&ge;4 months from the 3<sup>rd</sup> dose instead of 6 months) and the child is &ge;1 year of age, then the 4<sup>th</sup> dose does not need repeated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fifth dose: Given at 4 to 6 years of age, prior to starting school or kindergarten; if the fourth dose is given at &ge;4 years of age, the fifth dose may be omitted</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Catch-up immunization:</b> CDC (ACIP) Recommendations (ACIP [Robinson 2017]): <b>Note:</b> Do not restart the series. If doses have been given, begin the below schedule at the applicable dose number.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and children who start primary immunization series &ge;4 months of age through 6 years (prior to 7th birthday): DTaP (Daptacel, Infanrix): IM: 0.5 mL per dose for a total of 4 to 5 doses administered as follows: 3 doses at least 4 weeks apart, followed 6 months later with dose 4; a 5th dose may be given 6 months later (the 5th dose is not necessary if the child received the 4th dose at age 4 years or older)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;7 years and Adolescents not fully vaccinated against pertussis, or whose vaccination status is not known: IM: 0.5 mL single dose as part of the catch-up series; any additional doses needed would be Td.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Booster immunization</b> (Adacel, Boostrix): Children &ge;10 years, Adolescents, and Adults: <b>Note:</b> Tdap can be administered regardless of the interval between the last tetanus or diphtheria toxoid-containing vaccine. Tdap is currently recommended for a single dose only (CDC 60[1] 2011; CDC/ACIP 61[25] 2012), except pregnant females who should receive a Tdap dose during each pregnancy (preferably between 27 and 36 weeks' gestation) (CDC 62[7] 2013). <b>Note:</b> If Tdap was received as part of a catch-up series, Tdap should not be administered as the booster dose; use Td instead.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CDC (ACIP) recommendations:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents 10 to 18 years: Tdap (Adacel, Boostrix): IM: 0.5 mL per dose as a single dose. Tdap should be given as a single booster dose at age 11 or 12 years in children who have completed a childhood vaccination series, followed by booster doses of Td every 10 years.<b> Note:</b> If Tdap was given as part of catch-up dosing at 7 to 10 years of age, the 11 to 12 year booster is not needed. Regular Td booster immunizations should begin 10 years after the last dose of the primary series. Children who have not received Tdap at age 11 or 12 should receive a single dose of Tdap in place of a single Td booster dose (ACIP [Robinson 2017]; CDC 60[1] 2011]; CDC/ACIP [Broder 2006]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults &ge;19 years: Tdap (Adacel, Boostrix): IM: 0.5 mL per dose. A single dose of Tdap should be given to replace a single dose of the 10 year Td booster in patients who have not previously received Tdap or for whom vaccine status is not known. A single dose of Tdap is recommended for health care personnel who have not previously received Tdap and who have direct patient contact (CDC/ACIP [Kretsinger 2006]). Tdap should be administered regardless of interval since last tetanus- or diphtheria-containing vaccine (CDC/ACIP 61[25] 2012) except pregnant females who should receive a Tdap dose during each pregnancy (preferably during the early part of 27 and 36 weeks&rsquo; gestation) (ACIP [Kroger 2017]; CDC/ACIP 62[7] 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: Tdap (Adacel, Boostrix): Children &ge;10 years, Adolescents, and Adults: IM: 0.5 mL as a single dose, administered 5 years after last dose of tetanus toxoid, diphtheria toxoid, and/or pertussis-containing vaccine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tetanus prophylaxis in wound management</b> (CDC/ACIP [Broder 2006]): Children &ge;7 years, Adolescents, and Adults: Tdap (Adacel, Boostrix): IM: 0.5 mL as a single dose may be used as an alternative to Td vaccine when a tetanus toxoid-containing vaccine is needed for wound management, and in whom the pertussis component is also indicated. Tetanus prophylaxis in patients with wounds should be based on if the wound is clean or contaminated, the immunization status of the patient. Wound management includes proper use of tetanus toxoid and/or tetanus immune globulin (TIG), wound cleaning, and (if required) surgical debridement and the proper use of antibiotics. Patients with an uncertain or incomplete tetanus immunization status should have additional follow-up to ensure a series is completed. Patients with a history of Arthus reaction following a previous dose of a tetanus toxoid-containing vaccine should not receive a tetanus toxoid-containing vaccine until &gt;10 years after the most recent dose even if they have a wound that is neither clean nor minor. See table.</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Tetanus Prophylaxis Wound Management</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">History of Tetanus Immunization (Doses)</p></th>\n          <th colspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Clean, Minor Wounds</p></th>\n          <th colspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">All Other Wounds<sup>1</sup></p></th></tr></thead>\n      <tfoot valign=\"middle\">\n        <tr>\n          <td colspan=\"5\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>1</sup>Such as, but not limited to, wounds contaminated with dirt, feces, soil, and saliva; puncture wounds; wounds from crushing, tears, burns, and frostbite.</p></td></tr>\n        <tr>\n          <td colspan=\"5\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>2</sup>Tetanus toxoid in this chart refers to a tetanus toxoid containing vaccine. For children &le;6 years old DTaP (DT, if pertussis vaccine contraindicated) is preferred to tetanus toxoid alone. For children &ge;7 years of age, Adolescents, and Adults, Td preferred to tetanus toxoid alone; Tdap may be preferred if the patient has not previously been vaccinated with Tdap.</p></td></tr>\n        <tr>\n          <td colspan=\"5\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>3</sup>Yes, if &ge;10 years since last dose.</p></td></tr>\n        <tr>\n          <td colspan=\"5\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>4</sup>Yes, if &ge; 5 years since last dose.</p></td></tr>\n        <tr>\n          <td colspan=\"5\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;\">Abbreviations: <b>DT</b> = Diphtheria and Tetanus Toxoids (formulation for age &le;6 years); <b>DTaP</b> = Diphtheria and Tetanus Toxoids, and Acellular Pertussis (formulation for age &le;6 years; Daptacel, Infanrix); <b>Td</b> = Diphtheria and Tetanus Toxoids (formulation for age &ge;7 years; Tenivac&trade;); <b>TT</b> = Tetanus toxoid (adsorbed [formulation for age &ge;7 years]); <b>Tdap</b> = Diphtheria and Tetanus Toxoids, and Acellular Pertussis (Adacel or Boostrix [formulations for age &ge;7 years]); <b>TIG</b> = Tetanus Immune Globulin</p></td></tr></tfoot>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\"></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Tetanus toxoid <sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">TIG</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Tetanus toxoid <sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">TIG</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Uncertain or &lt;3 doses</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Yes</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">No</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Yes</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Yes</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">3 or more doses</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">No<sup>3</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">No</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">No<sup>4</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">No</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161248\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, suspension [Tdap, booster formulation]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adacel: Diphtheria 2 Lf units, tetanus 5 Lf units, and acellular pertussis antigens [detoxified pertussis toxin 2.5 mcg, filamentous hemagglutinin 5 mcg, pertactin 3 mcg, fimbriae (types 2 and 3) 5 mcg] per 0.5 mL (0.5 mL) [contains aluminum; may contain natural rubber/natural latex in prefilled syringe] </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Boostrix: Diphtheria 2.5 Lf units, tetanus 5 Lf units, and acellular pertussis antigens [inactivated pertussis toxin 8 mcg, filamentous hemagglutinin 8 mcg, pertactin 2.5 mcg] per 0.5 mL (0.5 mL) [contains aluminum and polysorbate 80; may contain natural rubber/natural latex in prefilled syringe]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, suspension [DTaP, active immunization formulation]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Daptacel: Diphtheria 15 Lf units, tetanus 5 Lf units, and acellular pertussis antigens [detoxified pertussis toxin 10 mcg, filamentous hemagglutinin 5 mcg, pertactin 3 mcg, fimbriae (types 2 and 3) 5 mcg] per 0.5 mL (0.5 mL) [preservative free; contains aluminum]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infanrix: Diphtheria 25 Lf units, tetanus 10 Lf units, and acellular pertussis antigens [inactivated pertussis toxin 25 mcg, filamentous hemagglutinin 25 mcg, pertactin 8 mcg] per 0.5 mL (0.5 mL) [preservative free; contains aluminum and polysorbate 80; prefilled syringes contain natural rubber/natural latex]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161236\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25734108\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DTaP: In the US, the appropriate CDC-approved  Vaccine Information Statement (VIS) must be provided to the patient prior to administering each dose of this vaccine; VIS is available at <a target=\"_blank\" href=\"http://www.cdc.gov/vaccines/hcp/vis/vis-statements/dtap.html&amp;token=AAHYoDAb5A/YSr8VQiRYJsJa+xtSDgw+x9go1noRHegLn8TcWE84hJbdbbfdAqbiCOgxMY984FLBv0YiMFNR1w==&amp;TOPIC_ID=12763\" target=\"_blank\">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/dtap.html</a>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tdap: In the US, the appropriate CDC-approved  Vaccine Information Statement (VIS) must be provided to the patient prior to administering each dose of this vaccine; VIS is available at <a target=\"_blank\" href=\"http://www.cdc.gov/vaccines/hcp/vis/vis-statements/tdap.html&amp;token=AAHYoDAb5A/YSr8VQiRYJsJa+xtSDgw+x9go1noRHegLn8TcWE84hJbdbbfdAqbifik+WgfcvRXQHsixPvGgsQ==&amp;TOPIC_ID=12763\" target=\"_blank\">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/tdap.html</a>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058018\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Shake vial well before withdrawing the dose; administer IM into midlateral aspect of the thigh in infants and small children; administer in the deltoid area to older children and adults; not for IV, intradermal, or SubQ administration. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection (ACIP [Kroger 2017]). To prevent syncope related injuries, adolescents and adults should be vaccinated while seated or lying down ACIP [Kroger 2017]). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address be entered into the patient's permanent medical record.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For patients at risk of hemorrhage following intramuscular injection, the vaccine should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23 gauge or smaller) should be used for the vaccination and firm pressure on the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161259\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Refrigerate at 2&deg;C to 8&deg;C (35&deg;F to 46&deg;F); do not freeze; discard if frozen. The following stability information has also been reported for Infanrix: May be stored at room temperature for up to 72 hours (Cohen 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058017\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DTaP (Daptacel, Infanrix): Active immunization for prevention of diphtheria, tetanus, and pertussis (FDA approved in ages 6 weeks through 6 years); has also been used for wound management for the prevention of tetanus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tdap:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adacel: Active booster immunization for prevention of diphtheria, tetanus, and pertussis (FDA approved in ages 10 to 64 years)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Boostrix: Active booster immunization for prevention of diphtheria, tetanus, and pertussis (FDA approved in ages &ge;10 years); has also been used for wound management for the prevention of tetanus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination for the following:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children 6 weeks to &lt;7 years (DTaP):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&bull; For primary immunization against diphtheria, tetanus, and pertussis (Use of diphtheria toxoid [ACIP 2000])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&bull; Pediatric patients wounded in bombings or similar mass casualty events, have penetrating injuries or nonintact skin exposure, and have an uncertain vaccination history should receive a tetanus booster with DTaP if no contraindications exist (CDC [Chapman 2008])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 7 to 10 years (Tdap):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&bull; Children not fully vaccinated against pertussis should receive a single dose of Tdap if no contraindications exist (CDC/ACIP 60[1] 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&bull; Children never vaccinated against diphtheria, tetanus, or pertussis, or whose vaccination status is not known should receive a series of three vaccinations containing tetanus and diphtheria toxoids and the first dose should be with Tdap (CDC/ACIP 60[1] 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;11 years and Adolescents (Tdap):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&bull; A single dose of Tdap as a booster dose in adolescents who have completed the recommended childhood DTaP vaccination series (preferred age of administration is 11 to 12 years) (CDC/ACIP 60[1] 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;11 years, Adolescents, and Adults (Tdap):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&bull; Persons wounded in bombings or similar mass casualty events and who cannot confirm receipt of a tetanus booster within the previous 5 years and who have penetrating injuries or nonintact skin exposure should receive a single dose of Tdap (CDC [Chapman 2008])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescent and Adult females: Pregnant females should receive a single dose with each pregnancy, preferably during the early part of 27 to 36 weeks' gestation (ACIP [Kroger 2017]; CDC/ACIP 62[7] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults &ge;19 years (including adults &ge;65 years) (Tdap): A single dose of Tdap should be given to all patients who have not previously received Tdap or for whom their vaccine status is unknown. Following administration of Tdap, Td vaccine should be used for routine boosters (ACIP [Kim 2017]). The following patients, who have not yet received Tdap or for whom vaccine status is not known, should receive a single dose of Tdap as soon as feasible:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&bull; Close contacts of children &lt;12 months of age: Tdap should ideally be administered at least 2 weeks prior to beginning close contact (CDC/ACIP 60[41], 2011; CDC/ACIP [Kretsinger 2006])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&bull; Health care providers with direct patient contact (CDC/ACIP [Kretsinger 2006])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Tdap is currently recommended for a single dose only (all age groups) (CDC/ACIP 60[1] 2011; CDC/ACIP 61[25] 2012) except pregnant females (CDC/ACIP 62[7] 2013)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2671735\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Adacel (Tdap) may be confused with Daptacel (DTaP)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Tdap (Adacel, Boostrix) may be confused with DTaP (Daptacel, Infanrix, Tripedia)</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Carefully review product labeling to prevent inadvertent administration of Tdap when DTaP is indicated. Tdap contains lower amounts of diphtheria toxoid and some pertussis antigens than DTaP.</p>\n        <p style=\"text-indent:0em;margin-left:2em;\">DTaP is indicated for use in persons &le;6 years of age</p>\n        <p style=\"text-indent:0em;margin-left:2em;\">Tdap is indicated for use in children &ge;10 years of age. If needed, Tdap can be used for children 7 to 10 years (CDC/ACIP, 60[1] 2011)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Guidelines are available in case of inadvertent administration of these products; refer to ACIP recommendations, February 2006 available at <a target=\"_blank\" href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/rr55e223a1.htm&amp;token=mjmpv7xMHRIW2nr+3NCnsbCRzI0l2D55/Qbax/5ovYd2Ipr9o4pHSFJtEeeVfugoYvFaLp3hNs8ejrHqGht//Q==&amp;TOPIC_ID=12763\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/rr55e223a1.htm</a></p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">DTaP: Diphtheria and tetanus toxoids and acellular pertussis vaccine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">DTP: Diphtheria and tetanus toxoids and pertussis vaccine (unspecified pertussis antigens)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">DTwP: Diphtheria and tetanus toxoids and whole-cell pertussis vaccine (no longer available on US market)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Tdap: Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161277\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at <a target=\"_blank\" href=\"https://vaers.hhs.gov/esub/index&amp;token=8m3rK0tzv73hmwLVujPJP0lWL2FxLWQizZTxo5kD83IMEaCGiDnUFaD+0my2cUJQ&amp;TOPIC_ID=12763\" target=\"_blank\">https://vaers.hhs.gov/esub/index</a>.</b>  In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:2em;text-align:justify;\">\n      <b>Daptacel, Infanrix</b> (incidence of erythema, swelling, and fever increases with successive doses): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Drowsiness, irritability, lethargy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Decreased appetite, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Erythema at injection site, local pain, localized edema, tenderness at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Crying (prolonged or persistent), fever, fussiness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rare but important or life-threatening: Anaphylaxis, angioedema, apnea, brain disease, bronchitis, cellulitis, cough, cyanosis, diarrhea, erythema, fatigue, headache, hypersensitivity reaction, hypotonia, hypotonic/hyporesponsive episode, immune thrombocytopenia, infantile spasm, injection site reaction (abscess, cellulitis, induration, mass, nodule, rash), lymphadenopathy, nausea, otalgia, peripheral edema, pruritus, respiratory tract infection, screaming, seizure, skin rash, sudden infant death syndrome, thrombocytopenia, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">\n      <b>Adacel, Boostrix: Note: Ranges presented, actual percent varies by product and age group</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Central nervous system: Chills, fatigue (more common in adolescents and adults), headache (more common in adolescents and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Dermatologic: Skin rash </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Endocrine &amp; metabolic: Increased arm circumference (children and adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Gastrointestinal: Gastrointestinal symptoms (includes abdominal pain, diarrhea, nausea, and/or vomiting; more common in adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Local: Erythema at injection site, pain at injection site (adolescents, adults, older adults), swelling at injection site (more common in adolescents and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Miscellaneous: Fever (&ge;38&deg;C [&ge;100.4&deg;F])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:2em;text-align:justify;\">\n      <b>Adacel, Boostrix</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Rare but important or life-threatening: Anaphylaxis, back pain, diabetes mellitus, encephalitis, facial paralysis, Guillain-Barre syndrome, hypersensitivity reaction, hypoesthesia, IgA vasculitis, injection site reaction (bruising, induration, inflammation, mass, nodule, pruritus, sterile abscess, warmth), lymphadenitis, lymphadenopathy, myalgia, myocarditis, myositis, nerve compression, paresthesia, peripheral edema (extensive), pruritus, seizure, syncope, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:2em;text-align:justify;\">\n      <b>Daptacel, Infanrix</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Rare but important or life-threatening: Anaphylaxis, angioedema, apnea, back pain, brain disease, bronchitis, cellulitis, cough, cyanosis, diabetes mellitus, diarrhea, encephalitis, erythema, facial paralysis, fatigue, Guillain-Barre syndrome, headache, hypersensitivity reaction, hypoesthesia, hypotonia, IgA vasculitis, immune thrombocytopenia, infantile spasm, injection site reaction (abscess, bruising, cellulitis, induration, inflammation, mass, nodule, pruritus, sterile abscess, rash, warmth), lymphadenopathy, nausea, otalgia, peripheral edema, pruritus, respiratory tract infection, screaming, seizure, skin rash, sudden infant death syndrome, thrombocytopenia, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161253\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to diphtheria, tetanus toxoids, pertussis, or any component of the formulation; progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy or progressive epilepsy (postpone until condition stabilized) (Infanrix only); encephalopathy occurring within 7 days of administration and not attributable to another cause; administration to children and adults &ge;7 years (Daptacel only)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161240\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Arthus-type hypersensitivity: Patients with a history of severe local reaction (Arthus-type) following a previous diphtheria toxoid or tetanus toxoid-containing vaccine dose should not be given further routine or emergency doses of Td more frequently than every 10 years, even if using for wound management with wounds that are not clean or minor; these patients generally have high serum antitoxin levels (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Reactions from previous dose: Carefully consider use in patients with history of any of the following effects from previous administration of any pertussis-containing vaccine: Fever &ge;105&deg;F (40.5&deg;C) within 48 hours of unknown cause; seizures with or without fever occurring within 3 days; persistent, inconsolable crying episodes lasting &ge;3 hours and occurring within 48 hours; collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Defer administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Guillain-Barr&eacute; syndrome: Use with caution if Guillain-Barr&eacute; syndrome occurred within 6 weeks of prior tetanus toxoid-containing vaccine (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurologic disorders: Use with caution in patients with progressive neurologic disease including infantile spasms, uncontrolled seizure, or a progressive encephalopathy, or conditions predisposing to seizures; ACIP guidelines recommend deferring immunization until health status can be assessed and condition stabilized (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticoagulant therapy: Use with caution in patients receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist. The use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and adverse events. When using combination vaccines, the minimum age for administration is the oldest minimum age for any individual component; the minimum interval between dosing is the greatest minimum interval between any individual component. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible; however, vaccination should not be deferred because a specific brand name is unavailable (ACIP [Kroger 2017]). Administration of Menactra (meningococcal MenACWY-D conjugate vaccine) one month after Daptacel has been shown to have reduced meningococcal antibody responses in children 4 to 6 years; these vaccines should be administered simultaneously or Menactra should be administered prior to Daptacel.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered immunocompetence: Consider deferring immunization during periods of severe immunosuppression (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy (including high dose corticosteroids); may have a reduced response to vaccination. May be used in patients with HIV infection. In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines. Inactivated vaccines should be administered &ge;2 weeks prior to planned immunosuppression when feasible; inactivated vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2017]; IDSA [Rubin 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Apnea has been reported following IM vaccine administration in premature infants; consider clinical status implications. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adacel: Formulated with the same antigens found in Daptacel, but with reduced quantities of tetanus and pertussis. Use in the primary immunization series or to complete the primary series has not been evaluated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Boostrix: Formulated with the same antigens found in Infanrix, but in reduced quantities. Use in the primary immunization series or to complete the primary series has not been evaluated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Latex: Packaging may contain natural latex rubber.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antipyretics: Per the manufacturer, antipyretic prophylaxis may be considered for patients at high risk for seizures. However, antipyretics have not been shown to prevent febrile seizures. Antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2017]). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Use of this vaccine for specific medical and/or other indications (eg, immunocompromising conditions, hepatic or kidney disease, diabetes) is also addressed in the ACIP Recommended Immunization Schedules (ACIP [Kim 2017]; CDC/ACIP [Robinson 2017]). Specific recommendations for vaccination in immunocompromised patients with asplenia, cancer, HIV infection, cerebrospinal fluid leaks, cochlear implants, hematopoietic stem cell transplant (prior to or after), sickle cell disease, solid organ transplant (prior to or after), or those receiving immunosuppressive therapy for chronic conditions as well as contacts of immunocompromised patients are available from the IDSA (Rubin 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299219\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161243\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12763&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Patients should receive inactivated vaccines prior to initiation of belimumab therapy whenever possible, due to the risk for an impaired response to the vaccine during belimumab therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<b> Exceptions: </b>Cytarabine (Liposomal).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Meningococcal (Groups A / C / Y and W-135) Diphtheria Conjugate Vaccine: Diphtheria and Tetanus Toxoids, and Acellular Pertussis Vaccine may diminish the therapeutic effect of Meningococcal (Groups A / C / Y and W-135) Diphtheria Conjugate Vaccine. More specifically, prior administration of the diphtheria and tetanus toxoids, and acellular pertussis vaccine may diminish antibody response to the meningococcal (groups A / C / Y / and W-135) diphtheria conjugate vaccine in some patients.  Management: Administer the meningococcal (groups A / C / Y and W-135) diphtheria conjugate vaccine (Menactra brand) before or concurrently with the diphtheria and tetanus toxoids, and acellular pertussis vaccine (Daptacel brand) in children 4 to 6 years of age.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Meningococcal Polysaccharide (Groups A / C / Y and W-135) Tetanus Toxoid Conjugate Vaccine: May diminish the therapeutic effect of Tetanus Toxoids Vaccines. Management: When possible, administer the meningococcal polysaccharide (groups A / C / Y and W-135) tetanus toxoid conjugate vaccine either together with or at least one month before a tetanus toxoids-containing vaccine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May diminish the therapeutic effect of Vaccines (Inactivated).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161245\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B/C (manufacturer specific) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161256\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Animal reproduction studies have not been conducted with all products; when conducted, adverse effects to the fetus were not observed in developmental toxicity studies. Inactivated bacterial vaccines have not been shown to cause increased risks to the fetus (ACIP [Kroger 2017]). Daptacel and Infanrix are not recommended for use in a pregnant female or any patient &ge;7 years of age. Using data collected from 2005-2010 VAERS, there were not any patterns of adverse maternal, fetal, or neonatal outcomes identified following maternal use of the Tdap vaccine (Zheteyeva 2012). Additional VAERS data collected between 2011 and 2015 (after the current recommendations for use in pregnancy were in effect), also did not observe any new or unexpected maternal or newborn adverse events following maternal vaccination (Moro 2016).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">All pregnant females should receive a single dose of Tdap during each pregnancy, regardless of previous vaccination status, preferably during the early part of 27 of 36 weeks gestation. Alternately, administration of Tdap can be given immediately postpartum to all females who have not previously been vaccinated with Tdap in order to protect the mother and infant from pertussis (ACIP [Kroger 2017]; CDC/ACIP 62[7] 2013). In case of an ongoing local pertussis epidemic, pregnant females should be vaccinated with Tdap for their own protection as is recommended for nonpregnant females, regardless of fetal gestational age. In addition, if a tetanus toxoid-containing vaccine is needed as standard care for wound management, Tdap may be given regardless of fetal gestational age if otherwise indicated. However, if Tdap is used prior to 27 to 36 weeks gestation in these instances, females should not receive more than 1 dose during the same pregnancy (ACOG 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Pregnancy registries have been established for females who may become exposed to Boostrix (888-452-9622) or Adacel (800-822-2463) while pregnant.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10160896\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Observe for syncope for 15 minutes following administration ACIP [Kroger 2017]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161239\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Promotes active immunity to diphtheria, tetanus, and pertussis by inducing production of specific antibodies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058021\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Adacel is formulated with the same antigens found in Daptacel but with reduced quantities of tetanus and pertussis; Boostrix is formulated with the same antigens found in Infanrix but in reduced quantities. Use of Adacel or Boostrix in the primary immunization series or to complete the primary series has not been evaluated. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The following guidance has been given for when the pediatric formulation is inadvertently given to a patient 7 to 18 years of age (ACIP [Robinson 2016]):</p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">&bull; For patients 7 to 10 years of age, the dose may count as part of the catch-up series. It may also count as the adolescent Tdap booster, or another Tdap booster can be given at age 11 to 12 years.</p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\"> &bull; For patients 11 to 18 years, the dose should be counted as the adolescent Tdap booster.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323115\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Adacel Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5-2-15.5 lf-mcg/0.5 (0.5 mL): $52.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Boostrix Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5-2.5-18.5 (0.5 mL): $47.61</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Daptacel Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15-23-5 lf-mcg/0.5 (0.5 mL): $35.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Infanrix Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25-58-10 (0.5 mL): $28.41</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161257\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adacel (AU, HR, MT, PH, PL, RO, SG, VN);</li>\n      <li>Adsorbed DT COQ (HK, TW);</li>\n      <li>Anatoxal Di Te Per Berna (PE);</li>\n      <li>Boostagen (TH);</li>\n      <li>Boostrix (AE, AT, AU, CO, CY, CZ, DE, ES, FI, HK, IE, IL, KW, LB, LK, LT, LU, MX, NZ, PH, PL, SA, SG);</li>\n      <li>Boostrix-IPV (GB);</li>\n      <li>Bustryks (UA);</li>\n      <li>D.T. COQ (MY);</li>\n      <li>Dif per tet all (MY, PH, PK);</li>\n      <li>DiTePer Anatoxal Berna Vaccine (HK, MY, PH);</li>\n      <li>DPT (TW);</li>\n      <li>Infanrix (AE, AT, BB, BE, BG, BM, BS, BZ, GY, HR, IT, JM, KW, LB, MX, NL, PL, QA, RO, SA, SE, SR, TT, TW);</li>\n      <li>P.D.T. Vax Purified (KR);</li>\n      <li>TRIAcelluvax (DE);</li>\n      <li>Tribik (JP);</li>\n      <li>Tripacel (AU, TH, TW);</li>\n      <li>Tripavac (PH);</li>\n      <li>Tripvac (IN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee Opinion No. 566: Update on immunization and pregnancy: tetanus, diphtheria, and pertussis vaccination. <i>Obstet Gynecol</i>. 2013;121(6):1411-1414.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-pediatric-drug-information/abstract-text/23812487 /pubmed\" target=\"_blank\" id=\"23812487 \">23812487 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Adacel (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed) [prescribing information]. Swiftwater, PA: Sanofi Pasteur Inc; March 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and e-ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-pediatric-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Broder KR, Cortese MM, Iskander JK, et al. Advisory Committee on Immunization Practices (ACIP). Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2006;55(RR-3):1-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-pediatric-drug-information/abstract-text/16557217/pubmed\" target=\"_blank\" id=\"16557217\">16557217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. <i>MMWR Morb Mortal Wkly Rep</i>. 2011;60(1):13-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-pediatric-drug-information/abstract-text/21228763/pubmed\" target=\"_blank\" id=\"21228763\">21228763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women &minus; Advisory Committee on Immunization Practices (ACIP), 2012. <i>MMWR Morb Mortal Wkly Rep</i>. 2013;62(7):131-135.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-pediatric-drug-information/abstract-text/23425962/pubmed\" target=\"_blank\" id=\"23425962\">23425962</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older &minus; Advisory Committee on Immunization Practices (ACIP), 2012 [published correction appears in <i>MMWR Morb Mortal Wkly Rep</i>. 2012;61(27):515]. <i>MMWR Morb Mortal Wkly Rep</i>. 2012;61(25):468-470. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6125a4.htm?s_cid=mm6125a4_e\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6125a4.htm?s_cid=mm6125a4_e</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-pediatric-drug-information/abstract-text/22739778/pubmed\" target=\"_blank\" id=\"22739778\">22739778</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged &lt;12 months &minus; Advisory Committee on Immunization Practices (ACIP), 2011. <i>MMWR Morb Mortal Wkly Rep</i>. 2011;60(41):1424-1426.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-pediatric-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Vaccines for children program, vaccines to prevent diphtheria, tetanus and pertussis. Resolution no. 6/11-2. Available at <a href=\"http://www.cdc.gov/vaccines/programs/vfc/downloads/resolutions/0611dtap.pdf\" target=\"_blank\">http://www.cdc.gov/vaccines/programs/vfc/downloads/resolutions/0611dtap.pdf</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-pediatric-drug-information/abstract-text/19373199/pubmed\" target=\"_blank\" id=\"19373199\">19373199</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chapman LE, Sullivent EE, Grohskopf LA, et al. Recommendations for postexposure interventions to prevent infection with hepatitis B virus, hepatitis C virus, or human immunodeficiency virus, and tetanus in persons wounded during bombings and other mass-casualty events &minus; United States, 2008: recommendations of the Centers for Disease Control and Prevention (CDC). <i>MMWR Recomm Rep</i>. 2008;57(RR-6):1-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-pediatric-drug-information/abstract-text/18668022/pubmed\" target=\"_blank\" id=\"18668022\">18668022</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen V, Jellinek SP, Teperikidis L, Berkovits E, Goldman WM. Room-temperature storage of medications labeled for refrigeration. <i>Am J Health-Syst Pharm</i>. 2007;64(16):1711-1715.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-pediatric-drug-information/abstract-text/17687059/pubmed\" target=\"_blank\" id=\"17687059\">17687059</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daptacel (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) [prescribing information]. Swiftwater, PA: Sanofi Pasteur Inc; October 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Infanrix (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension.<i> Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-pediatric-drug-information/abstract-text/12534540 /pubmed\" target=\"_blank\" id=\"12534540 \">12534540 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kim DK, Riley LE, Harriman KH, Hunter P, Bridges CB. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(5):136-138.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-pediatric-drug-information/abstract-text/28182599/pubmed\" target=\"_blank\" id=\"28182599\">28182599</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kretsinger K, Broder KR, Cortese MM, et al. Centers for Disease Control and Prevention; Advisory Committee on Immunization Practices; Healthcare Infection Control Practices Advisory Committee. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. <i>MMWR Recomm Rep</i>. 2006;55(RR-17):1-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-pediatric-drug-information/abstract-text/17167397/pubmed\" target=\"_blank\" id=\"17167397\">17167397</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kroger AT, Duchin J, Vazquez M. General best practice guidelines for immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Available at <a href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf\" target=\"_blank\">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed April 4, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prymula R, Siegrist CA, Chlibek R, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. <i>Lancet</i>. 2009;374(9698):1339-1350.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-pediatric-drug-information/abstract-text/19837254/pubmed\" target=\"_blank\" id=\"19837254\">19837254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson CL, Romero JR, Kempe A, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(5):134-135.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-pediatric-drug-information/abstract-text/28182607/pubmed\" target=\"_blank\" id=\"28182607\">28182607</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-pediatric-drug-information/abstract-text/24311479/pubmed\" target=\"_blank\" id=\"24311479\">24311479</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as a five-dose series. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2000;49(RR-13):1-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-pediatric-drug-information/abstract-text/11106289/pubmed\" target=\"_blank\" id=\"11106289\">11106289</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zheteyeva YA, Moro PL, Tepper NK, et al, &quot;Adverse Event Reports After Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines in Pregnant Women,&quot; <i>Am J Obstet Gynecol</i>, 2012, 207(1):59.e1-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-pediatric-drug-information/abstract-text/22727350/pubmed\" target=\"_blank\" id=\"22727350\">22727350</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12763 Version 127.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F161261\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F161262\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1058014\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1058008\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F161248\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F161236\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F25734108\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1058018\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F161259\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1058017\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F2671735\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F161277\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F161253\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F161240\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299219\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F161243\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F161245\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F161256\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10160896\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F161239\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1058021\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323115\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F161257\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12763|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-drug-information\" class=\"drug drug_general\">Diphtheria, tetanus toxoids, and acellular pertussis vaccine: Drug information</a></li><li><a href=\"topic.htm?path=diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-patient-drug-information\" class=\"drug drug_patient\">Diphtheria, tetanus toxoids, and acellular pertussis vaccine: Patient drug information</a></li></ul></div></div>","javascript":null}